Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H17NO2 |
Molecular Weight | 243.3015 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=NCCc1cccc2ccc(cc21)OC)O
InChI
InChIKey=YJYPHIXNFHFHND-UHFFFAOYSA-N
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
Molecular Formula | C15H17NO2 |
Molecular Weight | 243.3015 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24724693Curator's Comment:: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12750432 | https://www.ncbi.nlm.nih.gov/pubmed/12764576 | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693
Curator's Comment:: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12750432 | https://www.ncbi.nlm.nih.gov/pubmed/12764576 | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. Agomelatine is indicated for the treatment of major depressive episodes.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1945 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
0.1 nM [Ki] | ||
Target ID: CHEMBL1946 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
0.12 nM [Ki] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
6.2 null [pKi] | ||
Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
6.6 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VALDOXAN Approved UseTreatment of major depressive episodes. Launch Date1.23491516E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. | 2004 Sep |
|
Newer treatment studies for bipolar depression. | 2005 |
|
[Development of a new antidepressant : agomelatine]. | 2005 Oct |
|
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. | 2005 Oct |
|
[Depression and neuroplasticity: implication of serotoninergic systems]. | 2005 Sep-Oct |
|
Agomelatine: a preliminary review of a new antidepressant. | 2006 |
|
New directions for drug discovery. | 2006 |
|
Treatments in depression. | 2006 |
|
Therapeutic potential of melatonin ligands. | 2006 |
|
Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. | 2006 Aug |
|
Efficacy and tolerance profile of agomelatine and practical use in depressed patients. | 2006 Feb |
|
Sleep disturbances and depression: a challenge for antidepressants. | 2006 Feb |
|
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. | 2006 Feb |
|
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. | 2006 Feb |
|
Melatonin: Nature's most versatile biological signal? | 2006 Jul |
|
Prospects for the treatment of depression. | 2006 May |
|
[Agomelatine: the first "melatoninergic" antidepressant]. | 2006 Oct |
|
New antidepressants or more of the same? | 2007 |
|
Agomelatine and its therapeutic potential in the depressed patient. | 2007 Aug |
|
Emerging treatments for major depression. | 2007 Feb |
|
Agomelatine in the treatment of seasonal affective disorder. | 2007 Mar |
|
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. | 2007 Nov |
|
The interaction between the internal clock and antidepressant efficacy. | 2007 Oct |
|
Major depressive disorder, sleep EEG and agomelatine: an open-label study. | 2007 Oct |
|
[Pharmacotherapy of depression: recent developments]. | 2007 Sep 19 |
|
Effects of different antidepressant treatments on the core of depression. | 2008 |
|
Core symptoms of major depressive disorder: relevance to diagnosis and treatment. | 2008 |
|
Promising avenues of therapeutics for bipolar illness. | 2008 |
|
Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. | 2008 |
|
Gateways to clinical trials. | 2008 Apr |
|
Agomelatine treatment of major depressive disorder. | 2008 Dec |
|
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. | 2008 Jun 24 |
|
Melatonin and its agonists: an update. | 2008 Oct |
|
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. | 2008 Oct |
|
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. | 2008 Sep |
|
Addressing circadian rhythm disturbances in depressed patients. | 2008 Sep |
|
Innovation translates into antidepressant effectiveness. | 2008 Sep |
|
Agomelatine, an innovative pharmacological response to unmet needs. | 2008 Sep |
|
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. | 2009 |
|
Insomnia in patients with depression: some pathophysiological and treatment considerations. | 2009 |
|
Melatonin and melatonergic drugs on sleep: possible mechanisms of action. | 2009 |
|
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. | 2009 |
|
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. | 2009 |
|
The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. | 2009 Apr |
|
Pathophysiology of depression: role of sleep and the melatonergic system. | 2009 Feb 28 |
|
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. | 2009 Jul |
|
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. | 2009 Jun |
|
Agomelatine improves symptoms of generalised anxiety disorder. | 2009 May |
|
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. | 2009 Winter |
|
Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. | 2010 Jan |
Sample Use Guides
The recommended dose is 25 mg once daily taken orally at bedtime.
After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to
50 mg once daily, i.e. two 25 mg tablets, taken together at bedtime.
Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose
increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of
LFT monitoring.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27269050
hypothalamic suprachiasmatic nucleus firing rates were dose-dependently suppressed by 19.2-80.9% following perfusion of 0.04-0.32mM agomelatine (p<0.001, IC50=0.14mM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 22:17:30 UTC 2021
by
admin
on
Fri Jun 25 22:17:30 UTC 2021
|
Record UNII |
137R1N49AD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
||
|
WHO-VATC |
QN06AX22
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
THYMANAX (AUTHORIZED: DEPRESSIVE DISORDER, MAJOR)
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
||
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
||
|
WHO-ATC |
N06AX22
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
VALDOXAN (REFUSED: DEPRESSIVE DISORDER, MAJOR)
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C72684
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
99
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
137R1N49AD
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
AGOMELATINE
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
DB06594
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
SUB05286MIG
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
CHEMBL10878
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
138112-76-2
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
82148
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
7392
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
M1453
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | Merck Index | ||
|
138112-76-2
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY | |||
|
198
Created by
admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
Ki
|
||
|
TARGET -> AGONIST |
AGONIST
Ki
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |